Trusted Resources: News & Meetings
Latest announcements and gatherings
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
DUBLIN–(BUSINESS WIRE)–Apr. 10, 2023– Horizon Therapeutics plc (Nasdaq: HZNP) today announced positive and statistically significant topline results from its randomized, double-masked, placebo-controlled Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of adults with chronic TED and low CAS, which is a measure of disease activity. The totality of clinical trial data continues to strongly support the efficacy of TEPEZZA across a broad spectrum of TED patients regardless of disease activity or duration, with a well-established safety profile. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of TED – a serious, progressive, debilitating and potentially vision-threatening rare autoimmune disease.1
myBinderRelated Content
-
Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves HyperthyroidismContext: Supplemental selenium (Se) may...
-
Lugol’s Solution and Other Iodide Preparations: Perspectives and Research Directions in Graves’ DiseaseLugol's solution and other preparations ...
-
Which Factors Predict the Outcome of Radioactive Iodine Therapy of Graves’ Disease?Graves’ disease is the most common cau...
-
Hyperthyroidism and Graves’ DiseaseWhat is the Thyroid? The thyroid is a s...
-
Selenium in Graves Hyperthyroidism and OrbitopathyPurpose: To review the in vitro and in ...
-
University of Pittsburgh Medical Center – Multidisciplinary Thyroid CenterUniversity of Pittsburgh Medical Center ...
-
Pulmonary Arterial Hypertension in Patients with Hyperthyroid Graves’ Disease and Toxic Multinodular GoiterA number of case reports and small serie...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google